Ursprung des Netzwerks ersten Grades von Vincent P. Stanton
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Thiogenesis Therapeutics, Inc.
 Thiogenesis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thiogenesis Therapeutics, Inc. engages in the development of novel compounds that are based on thiols, thiol derivatives or S-H groups. The company was founded by Patrice P. Rioux and Vincent P. Stanton and is headquartered in Belmont, MA.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Vincent P. Stanton
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| REPLIGEN CORPORATION | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| MONOPAR THERAPEUTICS INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Corporate Officer/Principal | |
| Faculté de Médecine Paris | College/University | Doctorate Degree | |
| Pitié-Salpêtrière | College/University | Undergraduate Degree | |
| THIOGENESIS THERAPEUTICS, CORP. | Financial Conglomerates | Founder |
Statistik
International
| Vereinigte Staaten | 9 |
| Frankreich | 3 |
| Kanada | 2 |
Sektoral
| Health Technology | 8 |
| Consumer Services | 3 |
| Health Services | 2 |
| Finance | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 7 |
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 1 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Patrice Rioux | 12 |
- Börse
- Insiders
- Vincent P. Stanton
- Unternehmensverbindungen
